Information:
Fel:
ID
15114
Beskrivning
Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet; ODM derived from: https://clinicaltrials.gov/show/NCT00118950
Länk
https://clinicaltrials.gov/show/NCT00118950
Nyckelord
Versioner (1)
- 2016-05-16 2016-05-16 -
Uppladdad den
16 maj 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Diabetes Mellitus, Type 2 NCT00118950
Eligibility Diabetes Mellitus, Type 2 NCT00118950
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes Mellitus, Type 2 NCT00118950
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
diabetes type 2
Item
type-2 diabetes, defined as:
boolean
C0011849 (UMLS CUI [1,1])
C0441730 (UMLS CUI [1,2])
C0441730 (UMLS CUI [1,2])
age at onset
Item
age at onset of diabetes ≥ 40 years
boolean
C0001779 (UMLS CUI [1,1])
C0332162 (UMLS CUI [1,2])
C0332162 (UMLS CUI [1,2])
serum c-peptide
Item
fasting serum c-peptide ≥ 300 pmol/l or a non-fasting or glucagon-stimulated serum c-peptide ≥ 600 pmol/l
boolean
C0006558 (UMLS CUI [1])
ketonuria or ketoacidosis
Item
no history of ketonuria or ketoacidosis .
boolean
C0162275 (UMLS CUI [1,1])
C0011880 (UMLS CUI [1,2])
C0011880 (UMLS CUI [1,2])
bmi
Item
bmi ≤ 27 kg/m2.
boolean
C1305855 (UMLS CUI [1])
plasma-glucose
Item
fasting plasma-glucose ≥ 6.5 mmol/l after at least one month of diet-only treatment.
boolean
C0202042 (UMLS CUI [1])
hba1c
Item
hba1c ≤ 9.5% at ongoing oral anti-hyperglycaemic agents. hba1c ≥ 6.5% after minimum one month of diet-only treatment.
boolean
C0019018 (UMLS CUI [1])
weight-loss
Item
weight-loss of no more than 5.0 kg during the last 6 months prior to enrolment.
boolean
C1262477 (UMLS CUI [1,1])
C0439792 (UMLS CUI [1,2])
C0439792 (UMLS CUI [1,2])
diabetes type 1
Item
type-1 diabetes
boolean
C0011849 (UMLS CUI [1,1])
C0441729 (UMLS CUI [1,2])
C0441729 (UMLS CUI [1,2])
diabetes type
Item
insulin-treated type-2 diabetes
boolean
C0011849 (UMLS CUI [1,1])
C0441730 (UMLS CUI [1,2])
C0745343 (UMLS CUI [1,3])
C0441730 (UMLS CUI [1,2])
C0745343 (UMLS CUI [1,3])
diabetes
Item
secondary diabetes, heart-failure
boolean
C0011849 (UMLS CUI [1,1])
C0277555 (UMLS CUI [1,2])
C0018801 (UMLS CUI [1,3])
C0277555 (UMLS CUI [1,2])
C0018801 (UMLS CUI [1,3])
creatinine
Item
serum-creatinine above the upper limit
boolean
C0201976 (UMLS CUI [1])
asat
Item
serum-asat elevated more than 3 fold above the upper limit
boolean
C0201899 (UMLS CUI [1])
blood coagulating factor
Item
factor ii-vii-x decreased below 0.7
boolean
C0005789 (UMLS CUI [1,1])
C0547047 (UMLS CUI [1,2])
C0547047 (UMLS CUI [1,2])
life shortening comorbidity
Item
ongoing coexisting illnesses with a life-shortening prognosis
boolean
C0009488 (UMLS CUI [1,1])
C0023671 (UMLS CUI [1,2])
C0023671 (UMLS CUI [1,2])
mental retardation
Item
mental retardation or reduced intellectual behaviour
boolean
C0025362 (UMLS CUI [1])
pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
drug-abuse
Item
history of drug-abuse or hba1c>10.5% at two separate visits with at least one month interval during treatment-periods.
boolean
C0013146 (UMLS CUI [1])
C0019018 (UMLS CUI [2])
C0019018 (UMLS CUI [2])